Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials

Dealing with missing standard deviation and mean values in meta-analysis of continuous outcomes: a systematic review

(2018) Christopher J. Weir et al.   BMC Medical Research Methodology

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Primary and secondary progressive MS have a similar age at onset of progression – YES

(2017) Sandra Vukusic   Multiple Sclerosis Journal

Primary and secondary progressive MS have a similar age at onset of progression – NO

(2017) Helen Tremlett et al.   Multiple Sclerosis Journal

Primary and secondary progressive MS have a similar age at onset of progression – Commentary

(2017) Marcus Koch   Multiple Sclerosis Journal

Advancing trial design in progressive multiple sclerosis

(2017) David H Miller et al.   Multiple Sclerosis Journal

Progressive MS trials: Lessons learned

(2017) Carmen Tur et al.   Multiple Sclerosis Journal

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Primary and secondary progressive MS have a similar age at onset of progression – YES

(2017) Sandra Vukusic   Multiple Sclerosis Journal

Primary and secondary progressive MS have a similar age at onset of progression – NO

(2017) Helen Tremlett et al.   Multiple Sclerosis Journal

Primary and secondary progressive MS have a similar age at onset of progression – Commentary

(2017) Marcus Koch   Multiple Sclerosis Journal

Advancing trial design in progressive multiple sclerosis

(2017) David H Miller et al.   Multiple Sclerosis Journal

Progressive MS trials: Lessons learned

(2017) Carmen Tur et al.   Multiple Sclerosis Journal

Quantifying the relationship between increased disability and health care resource utilization, quality of life, work productivity, health care costs in patients with multiple sclerosis in the US

(2016) E. Jones et al.   BMC HEALTH SERVICES RESEARCH

A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study

(2016) Helga Westerlind et al.   Multiple Sclerosis Journal

Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note

(2016) Guoqiao Wang et al.   Multiple Sclerosis Journal

A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study

(2016) Helga Westerlind et al.   Multiple Sclerosis Journal

Baseline EDSS proportions in MS clinical trials affect the overall outcome and power: A cautionary note

(2016) Guoqiao Wang et al.   Multiple Sclerosis Journal

Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives

(2015) Daniel Ontaneda et al.   LANCET NEUROLOGY

Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression

(2015) Christian Röver et al.   PLoS One

Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial

(2014) Jeremy Chataway et al.   LANCET

Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression

(2013) Simon M Steinvorth et al.   Multiple Sclerosis Journal

Treatment trials in progressive MS—current challenges and future directions

(2013) Marcus W. Koch et al.   Nature Reviews Neurology

The cost burden of multiple sclerosis in the United States: a systematic review of the literature

(2013) Gabriel Adelman et al.   JOURNAL OF MEDICAL ECONOMICS

The quality of reports of randomized trials in multiple sclerosis: a review

(2012) Alessio Signori et al.   Multiple Sclerosis Journal

Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data

(2012) Jan-Patrick Stellmann et al.   PLoS One

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

The economic cost of brain disorders in Europe

(2011) J. Olesen et al.   EUROPEAN JOURNAL OF NEUROLOGY

Trends in annualized relapse rates in relapsing–remitting multiple sclerosis and consequences for clinical trial design

(2011) Richard Nicholas et al.   Multiple Sclerosis Journal

Evidence for a two-stage disability progression in multiple sclerosis

(2010) E. Leray et al.   BRAIN

The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability

(2010) Antonio Scalfari et al.   BRAIN

The natural history of secondary progressive multiple sclerosis

(2010) M. Koch et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Assessing changes in relapse rates in multiple sclerosis

(2010) Seidu Inusah et al.   Multiple Sclerosis Journal

A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis

(2010) Jeremy Chataway et al.   Multiple Sclerosis Journal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE